See more : Wison Engineering Services Co. Ltd. (2236.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Gilead Sciences, Inc. (GILD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gilead Sciences, Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Imagion Biosystems Limited (IBXXF) Income Statement Analysis – Financial Results
- Emak S.p.A. (EM.MI) Income Statement Analysis – Financial Results
- PHP Ventures Acquisition Corp. (PPHPR) Income Statement Analysis – Financial Results
- Super Tannery Limited (SUPTANERY.BO) Income Statement Analysis – Financial Results
- Bathurst Resources Limited (BTURF) Income Statement Analysis – Financial Results
Gilead Sciences, Inc. (GILD)
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.12B | 27.28B | 27.31B | 24.69B | 22.45B | 22.13B | 26.11B | 30.39B | 32.64B | 24.89B | 11.20B | 9.70B | 8.39B | 7.95B | 7.01B | 5.34B | 4.23B | 3.03B | 2.03B | 1.32B | 867.86M | 466.79M | 233.77M | 195.56M | 169.00M | 32.60M | 40.00M | 33.40M | 2.70M | 4.10M | 4.20M | 2.80M | 1.30M |
| Cost of Revenue | 6.50B | 5.66B | 6.60B | 4.57B | 4.68B | 4.85B | 4.37B | 4.26B | 4.01B | 3.79B | 2.86B | 2.47B | 2.12B | 1.87B | 1.60B | 1.13B | 768.77M | 433.32M | 260.33M | 166.59M | 112.69M | 69.72M | 43.76M | 21.50M | 16.90M | -2.20M | -1.80M | -3.60M | -3.20M | -2.80M | -1.70M | -1.00M | -800.00K |
| Gross Profit | 20.62B | 21.62B | 20.70B | 20.12B | 17.77B | 17.27B | 21.74B | 26.13B | 28.63B | 21.10B | 8.34B | 7.23B | 6.26B | 6.08B | 5.42B | 4.21B | 3.46B | 2.59B | 1.77B | 1.16B | 755.17M | 397.07M | 190.01M | 174.05M | 152.10M | 34.80M | 41.80M | 37.00M | 5.90M | 6.90M | 5.90M | 3.80M | 2.10M |
| Gross Profit Ratio | 76.04% | 79.26% | 75.82% | 81.48% | 79.18% | 78.07% | 83.26% | 85.98% | 87.73% | 84.78% | 74.48% | 74.53% | 74.67% | 76.48% | 77.24% | 78.87% | 81.83% | 85.68% | 87.17% | 87.42% | 87.02% | 85.06% | 81.28% | 89.00% | 90.00% | 106.75% | 104.50% | 110.78% | 218.52% | 168.29% | 140.48% | 135.71% | 161.54% |
| Research & Development | 6.92B | 4.98B | 5.36B | 5.04B | 9.11B | 5.02B | 3.73B | 5.10B | 3.01B | 2.85B | 2.12B | 1.76B | 1.23B | 1.07B | 939.92M | 721.77M | 591.03M | 383.86M | 277.72M | 223.55M | 164.87M | 134.76M | 185.55M | 131.57M | 112.90M | 75.30M | 59.20M | 41.90M | 0.00 | 26.00M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.26B | 4.90B | 4.51B | 4.36B | 3.60B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 826.00M | 778.00M | 735.00M | 795.00M | 784.00M | 587.00M | 600.00M | 618.00M | 601.00M | 393.00M | 216.00M | 160.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.09B | 5.67B | 5.25B | 5.15B | 4.38B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 34.70M | 7.60M | 22.40M | 9.10M | 6.10M |
| Other Expenses | 0.00 | -581.00M | -639.00M | -1.42B | 1.87B | 676.00M | 523.00M | 428.00M | 154.00M | 3.00M | -8.89M | -37.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.22M | 0.00 | 0.00 | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
| Operating Expenses | 13.67B | 10.65B | 10.61B | 10.19B | 13.49B | 9.07B | 7.61B | 8.50B | 6.44B | 5.84B | 3.82B | 3.22B | 2.47B | 2.12B | 1.89B | 1.53B | 1.30B | 957.52M | 656.97M | 526.35M | 425.25M | 316.06M | 310.69M | 226.37M | 203.80M | 109.10M | 87.70M | 73.10M | 37.90M | 36.40M | 24.10M | 10.10M | 6.90M |
| Cost & Expenses | 19.69B | 16.31B | 17.21B | 14.76B | 18.16B | 13.93B | 11.98B | 12.76B | 10.45B | 9.63B | 6.68B | 5.69B | 4.60B | 3.99B | 3.48B | 2.66B | 2.07B | 1.39B | 917.30M | 692.93M | 537.94M | 385.78M | 354.46M | 247.87M | 220.70M | 106.90M | 85.90M | 69.50M | 34.70M | 33.60M | 22.40M | 9.10M | 6.10M |
| Interest Income | 0.00 | 935.00M | 1.00B | 984.00M | 995.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.58M | 60.29M | 42.40M | 59.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 944.00M | 935.00M | 1.00B | 984.00M | 995.00M | 1.08B | 1.12B | 964.00M | 688.00M | 412.00M | 306.89M | 360.92M | 205.42M | 108.96M | 69.66M | 12.10M | 0.00 | 4.67B | 0.00 | 0.00 | 996.28M | 23.66M | 0.00 | 6.12M | 37.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.69B | 2.10B | 2.05B | 1.48B | 1.40B | 1.43B | 1.29B | 1.16B | 1.10B | 1.05B | 344.70M | 278.21M | 302.23M | 265.48M | 212.94M | 102.47M | 51.28M | 47.28M | 35.78M | 24.41M | 20.86M | 14.43M | 14.69M | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
| EBITDA | 10.50B | 8.85B | 11.33B | 4.13B | 7.56B | 10.31B | 15.93B | 19.22B | 23.45B | 16.32B | 4.86B | 4.25B | 4.16B | 4.29B | 3.78B | 2.84B | 2.22B | -576.83M | 1.15B | 688.18M | 350.78M | 81.01M | -106.00M | -40.31M | -39.10M | -65.10M | -56.90M | -31.60M | -28.80M | -31.30M | -16.50M | -5.30M | -4.00M |
| EBITDA Ratio | 38.71% | 38.10% | 34.63% | 34.46% | 27.42% | 40.11% | 56.10% | 59.43% | 68.47% | 61.34% | 40.31% | 40.95% | 45.99% | 50.60% | 50.94% | 51.47% | 52.38% | 134.71% | 56.54% | 48.54% | 97.90% | 23.88% | -116.58% | -19.15% | -9.05% | -275.77% | -153.00% | -139.52% | -1,259.26% | -753.66% | -495.24% | -257.14% | -369.23% |
| Operating Income | 7.61B | 7.33B | 7.41B | 7.03B | 4.29B | 8.20B | 14.12B | 17.63B | 22.19B | 15.27B | 4.52B | 4.01B | 3.79B | 3.96B | 3.53B | 2.68B | 2.16B | -758.75M | 1.11B | 631.69M | -158.68M | 81.01M | -120.69M | -52.32M | -51.70M | -74.30M | -45.90M | -36.10M | -32.00M | -29.50M | -18.20M | -6.30M | -4.80M |
| Operating Income Ratio | 28.05% | 26.87% | 27.12% | 28.47% | 19.10% | 37.06% | 54.10% | 58.02% | 68.00% | 61.33% | 40.39% | 41.33% | 45.20% | 49.84% | 50.34% | 50.20% | 51.17% | -25.07% | 54.78% | 47.69% | -18.28% | 17.35% | -51.63% | -26.75% | -30.59% | -227.91% | -114.75% | -108.08% | -1,185.19% | -719.51% | -433.33% | -225.00% | -369.23% |
| Total Other Income/Expenses | -746.00M | -1.52B | 872.00M | -2.40B | 873.00M | -401.00M | -595.00M | -536.00M | -534.00M | -409.00M | -315.78M | -398.20M | -138.84M | -48.67M | -27.27M | -5.84M | 105.83M | 120.55M | 50.69M | 24.73M | -8.86M | -7.61M | 178.14M | 10.41M | -13.90M | 22.40M | -500.00K | 15.00M | 5.20M | 9.90M | 4.30M | 1.90M | 800.00K |
| Income Before Tax | 6.86B | 5.81B | 8.28B | 1.67B | 5.16B | 7.80B | 13.53B | 17.10B | 21.66B | 14.86B | 4.21B | 3.61B | 3.65B | 3.91B | 3.50B | 2.73B | 2.27B | -638.21M | 1.16B | 656.42M | -167.53M | 73.40M | 57.45M | -41.91M | -65.60M | -55.90M | -27.60M | -21.10M | -26.80M | -25.30M | -13.90M | -4.40M | -4.00M |
| Income Before Tax Ratio | 25.30% | 21.31% | 30.32% | 6.76% | 22.99% | 35.25% | 51.82% | 56.26% | 66.36% | 59.69% | 37.57% | 37.23% | 43.54% | 49.23% | 49.95% | 51.25% | 53.67% | -21.09% | 57.28% | 49.56% | -19.30% | 15.72% | 24.57% | -21.43% | -38.82% | -171.47% | -69.00% | -63.17% | -992.59% | -617.07% | -330.95% | -157.14% | -307.69% |
| Income Tax Expense | 1.25B | 1.25B | 2.08B | 1.58B | -204.00M | 2.34B | 8.89B | 3.61B | 3.55B | 2.80B | 1.15B | 1.04B | 861.95M | 1.02B | 876.36M | 723.25M | 655.04M | 551.75M | 347.88M | 207.05M | -95.53M | 1.30M | 4.14M | 1.20M | 900.00K | -36.60M | -36.20M | -29.40M | -9.80M | -8.00M | -8.40M | -3.70M | -1.60M |
| Net Income | 5.67B | 4.59B | 6.23B | 89.00M | 5.39B | 5.46B | 4.63B | 13.50B | 18.11B | 12.10B | 3.07B | 2.59B | 2.80B | 2.90B | 2.64B | 2.01B | 1.62B | -1.19B | 813.91M | 449.37M | -72.00M | 72.10M | 52.27M | -56.78M | -66.50M | -56.10M | -28.00M | -21.70M | -27.40M | -25.70M | -14.10M | -4.50M | -4.00M |
| Net Income Ratio | 20.89% | 16.83% | 22.80% | 0.36% | 23.99% | 24.65% | 17.73% | 44.43% | 55.48% | 48.62% | 27.45% | 26.71% | 33.43% | 36.50% | 37.59% | 37.69% | 38.19% | -39.32% | 40.13% | 33.92% | -8.30% | 15.45% | 22.36% | -29.03% | -39.35% | -172.09% | -70.00% | -64.97% | -1,014.81% | -626.83% | -335.71% | -160.71% | -307.69% |
| EPS | 4.54 | 3.66 | 4.96 | 0.07 | 4.24 | 4.20 | 3.54 | 10.08 | 12.37 | 7.95 | 2.01 | 1.71 | 1.81 | 1.70 | 1.46 | 1.09 | 0.87 | -0.65 | 0.45 | 0.26 | -0.04 | 0.05 | 0.04 | -0.04 | -0.05 | -0.04 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
| EPS Diluted | 4.50 | 3.64 | 4.93 | 0.07 | 4.22 | 4.17 | 3.51 | 9.94 | 11.91 | 7.35 | 1.81 | 1.64 | 1.78 | 1.66 | 1.41 | 1.05 | 0.84 | -0.65 | 0.43 | 0.25 | -0.04 | 0.04 | 0.03 | -0.04 | -0.05 | -0.04 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 1.25B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B | 1.31B | 1.34B | 1.46B | 1.52B | 1.53B | 1.51B | 1.55B | 1.71B | 1.81B | 1.84B | 1.86B | 1.84B | 1.82B | 1.73B | 1.61B | 1.56B | 1.52B | 1.46B | 1.37B | 1.31B | 1.04B | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B | 1.32B | 1.36B | 1.52B | 1.65B | 1.69B | 1.58B | 1.58B | 1.75B | 1.87B | 1.92B | 1.93B | 1.84B | 1.90B | 1.86B | 1.61B | 1.65B | 1.62B | 1.46B | 1.37B | 1.31B | 1.04B | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. GILD revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi.
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with...
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences to close Seattle office; shutdown impacts 72 employees
Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to GeekWire on Wednesday.
Gilead Prices $3.5 Billion of Senior Unsecured Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion,...
Gilead initiated with a Buy at Citi
Citi initiated coverage of Gilead with a Buy rating and $125 price target. The firm says that despite the stock's near-term outperformance, it remains bullish based primarily on upside from Biktarvy led near-term HIV growth and lenacapavir driven long-term growth....
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's injectable HIV-1 capsid inhibitor, for the investigational...
GILD or VRTX: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed agents with varied dosing frequencies and...
Source: https://incomestatements.info
Category: Stock Reports